Free Trial

Arvinas (ARVN) Competitors

Arvinas logo
$9.46 +0.05 (+0.53%)
Closing price 10/15/2025 04:00 PM Eastern
Extended Trading
$9.44 -0.02 (-0.16%)
As of 04:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ARVN vs. OGN, BEAM, ALVO, CPRX, MLYS, BLTE, GLPG, CDTX, IDYA, and IRON

Should you be buying Arvinas stock or one of its competitors? The main competitors of Arvinas include Organon & Co. (OGN), Beam Therapeutics (BEAM), Alvotech (ALVO), Catalyst Pharmaceuticals (CPRX), Mineralys Therapeutics (MLYS), Belite Bio (BLTE), Galapagos (GLPG), Cidara Therapeutics (CDTX), IDEAYA Biosciences (IDYA), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry.

Arvinas vs. Its Competitors

Arvinas (NASDAQ:ARVN) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

In the previous week, Arvinas had 5 more articles in the media than Organon & Co.. MarketBeat recorded 7 mentions for Arvinas and 2 mentions for Organon & Co.. Arvinas' average media sentiment score of 0.60 beat Organon & Co.'s score of 0.40 indicating that Arvinas is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arvinas
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Organon & Co.
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Arvinas currently has a consensus price target of $16.18, suggesting a potential upside of 71.08%. Organon & Co. has a consensus price target of $17.33, suggesting a potential upside of 81.54%. Given Organon & Co.'s stronger consensus rating and higher possible upside, analysts plainly believe Organon & Co. is more favorable than Arvinas.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arvinas
2 Sell rating(s)
10 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.43
Organon & Co.
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.50

Organon & Co. has higher revenue and earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arvinas$263.40M2.64-$198.90M-$1.01-9.37
Organon & Co.$6.40B0.39$864M$2.693.55

95.2% of Arvinas shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 4.7% of Arvinas shares are held by insiders. Comparatively, 2.0% of Organon & Co. shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Organon & Co. has a net margin of 11.15% compared to Arvinas' net margin of -19.47%. Organon & Co.'s return on equity of 163.88% beat Arvinas' return on equity.

Company Net Margins Return on Equity Return on Assets
Arvinas-19.47% -12.01% -6.97%
Organon & Co. 11.15%163.88%6.99%

Arvinas has a beta of 2.39, suggesting that its share price is 139% more volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500.

Summary

Organon & Co. beats Arvinas on 9 of the 16 factors compared between the two stocks.

Get Arvinas News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARVN vs. The Competition

MetricArvinasMED IndustryMedical SectorNASDAQ Exchange
Market Cap$690.86M$3.36B$6.11B$10.45B
Dividend YieldN/A2.30%5.73%4.77%
P/E Ratio-9.3722.7785.4027.36
Price / Sales2.64483.38599.20137.65
Price / CashN/A46.7037.4661.86
Price / Book1.1610.5512.446.81
Net Income-$198.90M-$52.58M$3.32B$276.80M
7 Day Performance-1.36%0.09%0.60%0.42%
1 Month Performance23.82%15.61%10.53%7.86%
1 Year Performance-65.97%15.13%73.12%41.24%

Arvinas Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARVN
Arvinas
3.0273 of 5 stars
$9.46
+0.5%
$16.18
+71.1%
-63.5%$690.86M$263.40M-9.37420Analyst Forecast
Gap Down
OGN
Organon & Co.
4.8073 of 5 stars
$10.84
-1.5%
$17.33
+59.9%
-47.1%$2.82B$6.40B4.034,000
BEAM
Beam Therapeutics
3.1278 of 5 stars
$25.89
+0.5%
$46.40
+79.2%
+3.2%$2.62B$63.52M-5.75510
ALVO
Alvotech
3.6292 of 5 stars
$8.58
+3.1%
$14.00
+63.2%
-28.2%$2.59B$560.10M37.301,032Analyst Upgrade
Gap Up
CPRX
Catalyst Pharmaceuticals
4.8014 of 5 stars
$20.73
-0.5%
$33.20
+60.2%
+0.4%$2.54B$491.73M12.5680
MLYS
Mineralys Therapeutics
1.7881 of 5 stars
$38.01
-0.1%
$43.50
+14.4%
+216.4%$2.52BN/A-10.6828News Coverage
Insider Trade
BLTE
Belite Bio
2.2695 of 5 stars
$78.10
+3.3%
$96.00
+22.9%
+46.5%$2.49BN/A-50.3910High Trading Volume
GLPG
Galapagos
0.3273 of 5 stars
$35.55
-5.5%
$26.00
-26.9%
+16.0%$2.48B$275.61M0.001,310Upcoming Earnings
CDTX
Cidara Therapeutics
4.0855 of 5 stars
$96.45
-5.4%
$122.29
+26.8%
+938.5%$2.45B$1.27M-8.6790
IDYA
IDEAYA Biosciences
4.0256 of 5 stars
$27.49
-0.5%
$43.36
+57.7%
-7.9%$2.41B$7M-7.2580
IRON
Disc Medicine
2.4428 of 5 stars
$69.28
+2.2%
$98.30
+41.9%
+61.6%$2.41BN/A-15.5030

Related Companies and Tools


This page (NASDAQ:ARVN) was last updated on 10/16/2025 by MarketBeat.com Staff
From Our Partners